Dopaminergic Loss and Inclusion Body Formation in α-Synuclein Mice: Implications for Neurodegenerative Disorders
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
To elucidate the role of the synaptic protein α-synuclein in neurodegenerative disorders, transgenic mice expressing wild-type human α-synuclein were generated. Neuronal expression of human α-synuclein resulted in progressive accumulation of α-synuclein—and ubiquitin-immunoreactive inclusions in neurons in the neocortex, hippocampus, and substantia nigra. Ultrastructural analysis revealed both electron-dense intranuclear deposits and cytoplasmic inclusions. These alterations were associated with loss of dopaminergic terminals in the basal ganglia and with motor impairments. These results suggest that accumulation of wild-type α-synuclein may play a causal role in Parkinson's disease and related conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to point mutations linked to dominantly inherited PD (5–7), mounting evidence suggests that elevated levels of α-Syn are deleterious to dopaminergic neurons.”
From Repression of α-synuclein expression and toxicity by microRNA-7 (2009) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Self-citationDavies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,181
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.
Uéda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., & Saitoh, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11282 · Cited by 1,480
Self-citationIwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H. A., Kittel, A., & Saitoh, T. (1995) · Neuron · doi:10.1016/0896-6273(95)90302-x · Cited by 1,316
Self-citationPlaque-independent disruption of neural circuits in Alzheimer’s disease mouse models
Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., & Mucke, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3228 · Cited by 1,123
Self-citationIdentification of two distinct synucleins from human brain
Jakes, R., Spillantini, M. G., & Goedert, M. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00395-5 · Cited by 1,080
Cited by
Items 201–297 of 297
Lotharius, J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2395 · Cited by 269
Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice
Specht, C. G., & Schoepfer, R. (2001) · BMC Neuroscience · doi:10.1186/1471-2202-2-11 · Cited by 264
Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease
Dev, K. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00140-0 · Cited by 263
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity
Qiao, L., Hamamichi, S., Caldwell, K. A., Caldwell, G. A., Yacoubian, T. A., Wilson, S., Xie, Z.-L., Speake, L. D., Parks, R., Crabtree, D., et al. (2008) · Molecular Brain · doi:10.1186/1756-6606-1-17 · Cited by 263
Tabner, B. J., Turnbull, S., El-Agnaf, O. M. A., & Allsop, D. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00801-8 · Cited by 260
Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of α-Synuclein
Bussell, R., & Eliezer, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106777200 · Cited by 255
Shults, C. W., Rockenstein, E., Crews, L., Adame, A., Mante, M., Larrea, G., Hashimoto, M., Song, D., Iwatsubo, T., Tsuboi, K., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3527-05.2005 · Cited by 254
Self-citationAntioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 252
Etiology of Parkinson’s disease
Schapira, A. H. V. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s10 · Cited by 250
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Investigation of α-Synuclein Fibril Structure by Site-directed Spin Labeling
Chen, M., Margittai, M., Chen, J., & Langen, R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700368200 · Cited by 233
Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult
Lee, M., Hyun, D., Halliwell, B., & Jenner, P. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00149.x · Cited by 232
“It seems that function of wild-type a-synuclein is cell line- and insult-speci®c, since many previous studies suggest both protective and non-protective properties (Da Costa et al. 2000; Masliah et al. 2000; Zhou et al. 2000).”
ResultVolpicelli-Daley, L. A., Gamble, K. L., Schultheiss, C. E., Riddle, D. M., West, A. B., & Lee, V. M.-Y. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-02-0741 · Cited by 232
α-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton
Ordonez, D. G., Lee, M. K., & Feany, M. B. (2018) · Neuron · doi:10.1016/j.neuron.2017.11.036 · Cited by 227
Crews, L., Adame, A., Patrick, C., DeLaney, A., Pham, E., Rockenstein, E., Hansen, L., & Masliah, E. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1305-10.2010 · Cited by 222
Self-citationMethionine oxidation inhibits fibrillation of human α‐synuclein in vitro
Uversky, V. N., Yamin, G., Souillac, P. O., Goers, J., Glaser, C. B., & Fink, A. L. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02638-8 · Cited by 222
Mandal, P. K., Pettegrew, J. W., Masliah, E., Hamilton, R. L., & Mandal, R. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9140-9 · Cited by 219
“mice demonstrated severe learning, memory and motor deficits [27].”
BackgroundSelf-citationNeuronal Apoptosis in Neurodegeneration
Okouchi, M., Ekshyyan, O., Maracine, M., & Aw, T. Y. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1511 · Cited by 218
“-synuclein transgenic models are useful for studies on the early stages of PD (238).”
Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction
Park, J., Kim, S. Y., Cha, G.-H., Lee, S. B., Kim, S., & Chung, J. (2005) · Gene · doi:10.1016/j.gene.2005.06.040 · Cited by 213
Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment
Poehler, A.-M., Xiang, W., Spitzer, P., May, V. E. L., Meixner, H., Rockenstein, E., Chutna, O., Outeiro, T. F., Winkler, J., Masliah, E., et al. (2014) · Autophagy · doi:10.4161/auto.36436 · Cited by 212
Self-citationMeredith, G. E., Totterdell, S., Petroske, E., Santa Cruz, K., Callison, R. C., & Lau, Y.-S. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03514-x · Cited by 212
An, Y., Tang, L., Jiang, X., Chen, H., Yang, M., Jin, L., Zhang, S., Wang, C., & Zhang, W. (2010) · Chemistry – A European Journal · doi:10.1002/chem.201001654 · Cited by 211
Impaired dopamine release in Parkinson’s disease
Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R. (2023) · Brain · doi:10.1093/brain/awad064 · Cited by 207
“TH, the rate-limiting enzyme in DA synthesis, has been shown to have decreased protein levels or decreased activity in models of Parkinson’s disease carrying mutations in LRRK2, SNCA, DJ-1 and PINK1.”
BackgroundPham, E., Crews, L., Ubhi, K., Hansen, L., Adame, A., Cartier, A., Salmon, D., Galasko, D., Michael, S., Savas, J. N., et al. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07719.x · Cited by 206
Self-citationProteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease
McNaught, K. S. P., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10512 · Cited by 203
Luibl, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25843 · Cited by 203
Mechanisms of Suppression of α-Synuclein Neurotoxicity by Geldanamycin in Drosophila
Auluck, P. K., Meulener, M. C., & Bonini, N. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412106200 · Cited by 203
Alpha-synuclein and transgenic mouse models
Fernagut, P.-O., & Chesselet, M.-F. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.001 · Cited by 200
“, 2002) but also wild-type a-syn (Masliah et al., 2000) induced only a mild motor impairment, but associated with dopaminergic deficits.”
BackgroundInfluentialα‐Synuclein produces a long‐lasting increase in neurotransmitter release
Liu, S., Ninan, I., Antonova, I., Battaglia, F., Trinchese, F., Narasanna, A., Kolodilov, N., Dauer, W., Hawkins, R. D., & Arancio, O. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600451 · Cited by 198
The role of α-synuclein in neurodegenerative diseases
Bennett, M. C. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.010 · Cited by 197
Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity
Tabrizi, S. J. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.18.2683 · Cited by 197
“The mice overexpressing human wildtype α-synuclein developed intraneuronal inclusions, but no increased cell death of tyrosine hydroxylase (TH)-positive neurons (13).”
BackgroundResultInfluentialZhang, Z., Kang, S. S., Liu, X., Ahn, E. H., Zhang, Z., He, L., Iuvone, P. M., Duong, D. M., Seyfried, N. T., Benskey, M. J., et al. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3433 · Cited by 195
The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease
Zuo, L., & Motherwell, M. S. (2013) · Gene · doi:10.1016/j.gene.2013.07.085 · Cited by 194
Paumier, K. L., Sukoff Rizzo, S. J., Berger, Z., Chen, Y., Gonzales, C., Kaftan, E., Li, L., Lotarski, S., Monaghan, M., Shen, W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070274 · Cited by 192
“Previous studies show significant behavioral and synaptic impairment in mice over-expressing wild type [18,19,20] or mutant a-syn [13,14,21,22,23]; however, a majority of these studies evaluate behavioral function at a finite time point, usually late in the course of disease when behavioral”
BackgroundKida, K., Yamada, M., Tokuda, K., Marutani, E., Kakinohana, M., Kaneki, M., & Ichinose, F. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3671 · Cited by 191
Chen, L., Xie, Z., Turkson, S., & Zhuang, X. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0089-14.2015 · Cited by 187
Paiva, I., Pinho, R., Pavlou, M. A., Hennion, M., Wales, P., Schütz, A.-L., Rajput, A., Szegő, É. M., Kerimoglu, C., Gerhardt, E., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx114 · Cited by 185
The concept of alpha-synuclein as a prion-like protein: ten years after
Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2814-1 · Cited by 183
Gorbatyuk, M. S., Shabashvili, A., Chen, W., Meyers, C., Sullivan, L. F., Salganik, M., Lin, J. H., Lewin, A. S., Muzyczka, N., & Gorbatyuk, O. S. (2012) · Molecular Therapy · doi:10.1038/mt.2012.28 · Cited by 180
Lewy Body Pathology in Alzheimer's Disease
Kotzbauer, P. T., Tojanowski, J. Q., & Lee, V. M. V. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:225 · Cited by 177
“When overexpressed in transgenic mice, human αsynuclein produces cytoplasmic and nuclear inclusions in multiple neuronal populations, including the SN (Masliah et al., 2000).”
Monti, B., Gatta, V., Piretti, F., Raffaelli, S. S., Virgili, M., & Contestabile, A. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9090-5 · Cited by 175
“Furthermore, while contrasting results have been obtained regarding overexpression of a-synuclein on neurotoxicity toward nigral dopaminergic neurons in intact animals ( Masliah et al. 2000; Matsuoka et al. 2001; Rathke-Hartlieb et al. 2001; Kirik et al. 2002; Yamada et al. 2004), transgenic overexpression was neuropr…”
ResultRisk factors for dopaminergic neuron loss in human α‐synuclein transgenic mice
Thiruchelvam, M. J., Powers, J. M., Cory‐Slechta, D. A., & Richfield, E. K. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03139.x · Cited by 174
Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi
Sapru, M. K., Yates, J. W., Hogan, S., Jiang, L., Halter, J., & Bohn, M. C. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.12.024 · Cited by 173
Béraud, D., Hathaway, H. A., Trecki, J., Chasovskikh, S., Johnson, D. A., Johnson, J. A., Federoff, H. J., Shimoji, M., Mhyre, T. R., & Maguire-Zeiss, K. A. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9401-0 · Cited by 172
“…far, in some in vivo and in vitro models, α-synuclein overexpression, accumulation and/or oligomer formation is accompanied by cell dysfunction or death (El-Agnaf et al. 1998; Masliah et al. 2000; Lee et al. 2001; Kirik et al. 2002; Danzer et al. 2007; Periquet et al. 2007; Desplats et al. 2009).”
BackgroundSalivary biomarkers for the diagnosis and monitoring of neurological diseases
Farah, R., Haraty, H., Salame, Z., Fares, Y., Ojcius, D. M., & Said Sadier, N. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.03.004 · Cited by 170
Naseer, A., Rani, M., Naz, S., Razzak, M. I., Imran, M., & Xu, G. (2020) · Neural Computing and Applications · doi:10.1007/s00521-019-04069-0 · Cited by 170
RetractedUpdate on the genetics of Parkinson's disease
Gasser, T. (2007) · Movement Disorders · doi:10.1002/mds.21676 · Cited by 168
Neuropathology in Mice Expressing Mouse Alpha-Synuclein
Rieker, C., Dev, K. K., Lehnhoff, K., Barbieri, S., Ksiazek, I., Kauffmann, S., Danner, S., Schell, H., Boden, C., Ruegg, M. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024834 · Cited by 168
“Altogether the findings seem to suggest that fibrillar, as well as other types of aSN aggregates, are associated with pathophysiological effects of aSN in vivo [6,8,9,18].”
BackgroundMethionine oxidation, α-synuclein and Parkinson's disease
Glaser, C. B., Yamin, G., Uversky, V. N., & Fink, A. L. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2004.10.008 · Cited by 168
Nitration inhibits fibrillation of human α‐synuclein in vitro by formation of soluble oligomers
Yamin, G., Uversky, V. N., & Fink, A. L. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00367-3 · Cited by 167
Price, D. L., Koike, M. A., Khan, A., Wrasidlo, W., Rockenstein, E., Masliah, E., & Bonhaus, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-34490-9 · Cited by 165
Self-citationGene–environment interactions: Key to unraveling the mystery of Parkinson's disease
Gao, H.-M., & Hong, J.-S. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.03.005 · Cited by 165
MicroRNAs in Parkinson's disease
Mouradian, M. M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.046 · Cited by 165
The Two-stage Pathway of Ataxin-3 Fibrillogenesis Involves a Polyglutamine-independent Step
Ellisdon, A. M., Thomas, B., & Bottomley, S. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601470200 · Cited by 164
Plasma α-synuclein is decreased in subjects with Parkinson's disease
Li, Q.-X., Mok, S. S., Laughton, K. M., McLean, C. A., Cappai, R., Masters, C. L., Culvenor, J. G., & Horne, M. K. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.12.006 · Cited by 160
“Studies in mouse models that either lack the αSN gene (knock-out) or overexpress human αSN (transgenic) support a role of αSN in the development of PD (Abeliovich et al., 2000; Dauer et al., 2002; Giasson et al., 2002; Lee et al., 2002; Masliah et al., 2000).”
BackgroundKaylor, J., Bodner, N., Edridge, S., Yamin, G., Hong, D.-P., & Fink, A. L. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.08.046 · Cited by 159
Iwata, A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg283 · Cited by 159
Wakamatsu, M., Ishii, A., Iwata, S., Sakagami, J., Ukai, Y., Ono, M., Kanbe, D., Muramatsu, S.-I., Kobayashi, K., Iwatsubo, T., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.017 · Cited by 158
Kim, C., Spencer, B., Rockenstein, E., Yamakado, H., Mante, M., Adame, A., Fields, J. A., Masliah, D., Iba, M., Lee, H.-J., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0276-2 · Cited by 157
“To determine the role of TLR2 in α-synuclein pathology, we delivered either LV-control or LV-TLR2 into non-tg and α-syn-tg mice expressing human wild-type α-synuclein under the PDGF-β promoter (D line) [21].”
MethodSelf-citationA molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides
Gallardo, G., Schlüter, O. M., & Südhof, T. C. (2008) · Nature Neuroscience · doi:10.1038/nn2058 · Cited by 145
Park, J., Kim, K. S., Lee, S., Ryu, J., Chung, K. C., Choo, Y., Jou, I., Kim, J., & Park, S. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06150.x · Cited by 135
Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy
Kim, C., Rockenstein, E., Spencer, B., Kim, H.-K., Adame, A., Trejo, M., Stafa, K., Lee, H.-J., Lee, S.-J., & Masliah, E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.044 · Cited by 135
Self-citationRathke‐Hartlieb, S., Kahle, P. J., Neumann, M., Ozmen, L., Haid, S., Okochi, M., Haass, C., & Schulz, J. B. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00366.x · Cited by 128
“It has been reported that mice overexpressing human wild-type (WT) aSYN under the control of the human platelet-derived growth factor (PDGF)-b promoter showed decreases in locomotor performance and DA markers (Masliah et al. 2000).”
BackgroundBurke, K. A., Yates, E. A., & Legleiter, J. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00017 · Cited by 127
“Transgenic mice, unlike human patients, exhibited neurodegeneration and inclusions comprised of fine granular material and clear vacuoles, not fibrils (Masliah et al., 2000).”
BackgroundMembers, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124
“Accumulation of ASYN, either as a consequence of endogenous disturbances of proteostasis, experimental blockade of the proteasomal system, or by overexpression of its wild-type or mutant forms, leads to the disassembly of microtubules and, ultimately, to axonal damage (Esposito et al. 2007; Kirik et al. 2003; Masliah…”
BackgroundLeon, J., Moreno, A. J., Garay, B. I., Chalkley, R. J., Burlingame, A. L., Wang, D., & Dubal, D. B. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.024 · Cited by 123
Nishie, M., Mori, F., Yoshimoto, M., Takahashi, H., & Wakabayashi, K. (2004) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2004.00564.x · Cited by 123
α-Synuclein Lowers p53-dependent Apoptotic Response of Neuronal Cells
Alves da Costa, C., Paitel, E., Vincent, B., & Checler, F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207825200 · Cited by 122
Lou, H., Montoya, S. E., Alerte, T. N. M., Wang, J., Wu, J., Peng, X., Hong, C.-S., Friedrich, E. E., Mader, S. A., Pedersen, C. J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100867 · Cited by 115
Tanji, K., Mori, F., Mimura, J., Itoh, K., Kakita, A., Takahashi, H., & Wakabayashi, K. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0676-z · Cited by 102
Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model
Kohl, Z., Winner, B., Ubhi, K., Rockenstein, E., Mante, M., Münch, M., Barlow, C., Carter, T., Masliah, E., & Winkler, J. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07933.x · Cited by 101
Self-citationProgress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Inflammation in transgenic mouse models of neurodegenerative disorders
Schwab, C., Klegeris, A., & McGeer, P. L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.013 · Cited by 97
Parkinsons Disease and other α-Synucleinopathies
Goedert, M. (2001) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2001.047 · Cited by 96
Glial cell death induced by overexpression of α‐synuclein
Stefanova, N., Klimaschewski, L., Poewe, W., Wenning, G. K., & Reindl, M. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1171 · Cited by 93
Ugalde, C. L., Finkelstein, D. I., Lawson, V. A., & Hill, A. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13772 · Cited by 92
“…transgenic animal models that express human wild-type a-syn, or a-syn containing PD-associated mutations, spontaneously develop a-syn pathology and neurological illness and are used to model disease (Feany and Bender 2000; Kahle et al. 2000; Masliah et al. 2000; van der Putten et al. 2000).”
BackgroundFuentes, R., Petersson, P., & Nicolelis, M. A. L. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07417.x · Cited by 85
Hashimoto, M., & Masliah, E. (2003) · Neurochemical Research · doi:10.1023/a:1026073324672 · Cited by 78
“Furthermore, expression of human -synuclein in some transgenic (tg) mouse lines (130) and fly recapitulates several aspects of PD, such as formation of inclusion bodies and dysfunction of dopaminergic neurons (131).”
BackgroundSelf-citationUpregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease
Kasen, A., Houck, C., Burmeister, A. R., Sha, Q., Brundin, L., & Brundin, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105654 · Cited by 78
Parkinson’s disease: a rethink of rodent models
Melrose, H. L., Lincoln, S. J., Tyndall, G. M., & Farrer, M. J. (2006) · Experimental Brain Research · doi:10.1007/s00221-006-0461-3 · Cited by 74
“…accumulation of -synuclein (van der Putten et al. 2000; Kahle et al. 2001; Masliah et al. 2001), reduced dopaminergic (tyrosine hydroxylase positive) nerve terminals in the striatum and motor abnormalities (Masliah et al. 2000; van der Putten et al. 2000; Masliah et al. 2001; Fleming et al. 2004).”
BackgroundWongkongkathep, P., Han, J. Y., Choi, T. S., Yin, S., Kim, H. I., & Loo, J. A. (2018) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-018-2002-2 · Cited by 71
Cebrián, C., Loike, J. D., & Sulzer, D. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_356 · Cited by 65
ROCKENSTEIN, E., CREWS, L., & MASLIAH, E. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.013 · Cited by 65
Self-citationBrain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64
Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits
Larson, M. E., Greimel, S. J., Amar, F., LaCroix, M., Boyle, G., Sherman, M. A., Schley, H., Miel, C., Schneider, J. A., Kayed, R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704698114 · Cited by 61
“We speculate that this apparent discrepancy between these two studies might be because of the fact that hSYN-line D mice elicit LB inclusions as early as 3 mo of age and that motor function is compromised in bigenic hAPP/hSYN at 6 mo (52).”
ResultWu, X., Liang, Y., Jing, X., Lin, D., Chen, Y., Zhou, T., Peng, S., Zheng, D., Zeng, Z., Lei, M., et al. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2494-y · Cited by 55
Wan, T., Weir, E. J., Johnson, M., Korolchuk, V. I., & Saretzki, G. C. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101953 · Cited by 52
“These mice express the transgene mainly in the neocortex, hippocampus as well as the olfactory bulb (Masliah et al., 2000; Amschl et al., 2013) while the substantia nigra, like in other transgenic PD models, seems much less involved than in the human disease pathology.”
BackgroundMethodInfluentialInhibition of lysosomal functions reduces proteasomal activity
Qiao, L., & Zhang, J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.085 · Cited by 50
Emamzadeh, F. N., Aojula, H., McHugh, P. C., & Allsop, D. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.02.042 · Cited by 42
Rho GTPase regulation of α-synuclein and VMAT2: Implications for pathogenesis of Parkinson's disease
Zhou, Z., Kim, J., Insolera, R., Peng, X., Fink, D. J., & Mata, M. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.06.002 · Cited by 41
Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson’s disease
Andersen, J. K. (2003) · Neurotoxicity Research · doi:10.1007/bf03033150 · Cited by 40
“Transgenic fly and mouse models of in vivo α-synuclein overexpression in the brain, which enhance aggregation of the protein, are associated with neurotoxicity (Feany and Bender 2000; Masliah et al., 2000 ).”
BackgroundCeftriaxone Protects Astrocytes from MPP+ via Suppression of NF-ΚB/JNK/c-Jun Signaling
Zhang, Y., Zhang, X., & Qu, S. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8845-z · Cited by 39
“PD is characterized by selective loss of dopaminergic neurons and the formation of Lewy bodies in the substantia nigra pars compacta (SNc) [4, 5].”
Hunn, B. H. M., Vingill, S., Threlfell, S., Alegre-Abarrategui, J., Magdelyns, M., Deltheil, T., Bengoa-Vergniory, N., Oliver, P. L., Cioroch, M., Doig, N. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.029 · Cited by 38
Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies
Kwon, S., Iba, M., Masliah, E., & Kim, C. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.5.547 · Cited by 35
Self-citationHuntington, T. E., & Srinivasan, R. (2021) · Aging and disease · doi:10.14336/ad.2021.0517 · Cited by 34
“Transgenic mice expressing either the mutant or wildtype strains of human a-syn were the first animal models to overexpress a-syn[134-136].”
BackgroundNeurofilament-Immunoreactive Neurons in Alzheimer's Disease and Dementia with Lewy Bodies
Shepherd, C. E., McCann, H., Thiel, E., & Halliday, G. M. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0469 · Cited by 34
Neuroglia in neurodegeneration: Alzheimer, Parkinson, and Huntington disease
Lim, D., Matute, C., Cavaliere, F., & Verkhratsky, A. (2025) · Handbook of Clinical Neurology · doi:10.1016/b978-0-443-19102-2.00012-0 · Cited by 8
Metadata
- Authors
- Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L.
- Venue
- Science
- Published
- 2000-02-18
- Volume
- 287
- Issue
- 5456
- Pages
- 1265-1269
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2025922492
- Cited by
- 1,765
- References
- 25
- FWCI
- 77.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.